Resource Summary Report

Generated by RRID on Sep 9, 2026

Granzyme B Monoclonal Antibody (GB11), APC

RRID:AB_2536539
Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# GRB05, RRID:AB_2536539

Antibody Information

URL: http://antibodyregistry.org/AB_2536539

Proper Citation: Thermo Fisher Scientific Cat# GRB05, RRID:AB_2536539

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow (Assay-dependent)

Antibody Name: Granzyme B Monoclonal Antibody (GB11), APC

Description: This monoclonal targets Granzyme B

Target Organism: human

Clone ID: Clone GB11

Defining Citation: PMID:24762408, PMID:17312126, PMID:16357323, PMID:25954597, PMID:17569889, PMID:22006977

Antibody ID: AB_2536539

Vendor: Thermo Fisher Scientific

Catalog Number: GRB05

Record Creation Time: 20231110T035505+0000

Record Last Update: 20260831T211645+0000

Ratings and Alerts

No rating or validation information has been found for Granzyme B Monoclonal Antibody (GB11), APC.

No alerts have been found for Granzyme B Monoclonal Antibody (GB11), APC.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Sakrepatna Nagaraj A, et al. (2026) Ex Vivo Immuno-Oncology Platform Reveals Spatial T-cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer. Cancer immunology research, 14(4), 625.

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome. Immunity, 59(5), 1398.

Yu J, et al. (2026) 6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation. Neuron, 114(14), 2532.

Osorio JC, et al. (2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer cell.

Praiss AM, et al. (2025) Evolution of tumor stress response during cytoreductive surgery for ovarian cancer. iScience, 28(5), 112317.

Launonen IM, et al. (2024) Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer cell, 42(12), 2045.

Van Der Byl W, et al. (2024) The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. Immunity, 57(6), 1324.

Pedde AM, et al. (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. Cell reports, 43(11), 114855.

Bayerl F, et al. (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity, 56(6), 1341.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer cell, 41(8), 1498.

Nixon BG, et al. (2022) Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity, 55(11), 2044.

Chen Y, et al. (2022) Oncogenic collagen I homotrimers from cancer cells bind to ?3?1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer cell, 40(8), 818.

Zhao H, et al. (2021) Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity. Cell reports, 37(10), 110083.

Dege C, et al. (2020) Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. Developmental cell, 53(2), 229.

?ledzi?ska A, et al. (2020) Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells. Immunity, 52(1), 151.

Smith NL, et al. (2018) Developmental Origin Governs CD8+ T Cell Fate Decisions during Infection. Cell, 174(1), 117.